Can I Take Alpha-Lipoic Acid with GHK-Cu?

What Are GHK-Cu and Alpha-Lipoic Acid, and Why Do People Combine Them?

GHK-Cu is the copper salt of the tripeptide glycyl-L-histidyl-L-lysine. It occurs naturally in human plasma, saliva, and urine, and plasma concentrations fall from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 [1]. Compounded GHK-Cu preparations (topical, injectable) are used in clinical practice for wound healing, collagen synthesis stimulation, and skin rejuvenation under 503A compounding pharmacy rules.

Alpha-lipoic acid is a naturally occurring dithiol compound synthesized in mitochondria. It functions as a cofactor for pyruvate dehydrogenase and as a broad-spectrum antioxidant capable of scavenging reactive oxygen species in both aqueous and lipid compartments [2]. Supplemental ALA is sold in racemic (R/S-ALA) and pure R-ALA forms, typically in doses from 100 mg to 600 mg daily.

People combine these two agents because the goals often overlap: both are promoted for skin quality, oxidative stress reduction, and anti-aging protocols. That overlap does not make the combination automatically safe to ignore.

GHK-Cu's Mechanism at the Tissue Level

GHK-Cu binds copper(II) with a dissociation constant of approximately 10^-16 M, one of the tightest copper-binding affinities among naturally occurring peptides [1]. Once bound, the complex activates collagen and glycosaminoglycan synthesis, upregulates superoxide dismutase, and modulates TGF-beta signaling in fibroblasts. A 2018 review in Biomolecules catalogued over 50 genes regulated by GHK, spanning wound repair, anti-inflammatory, and antioxidant pathways [1].

How ALA Works as an Antioxidant and Metal Chelator

ALA reduces oxidized glutathione back to its active form and also directly chelates divalent and trivalent metal ions, including iron(III), copper(II), zinc(II), and cadmium [2]. This chelation activity is the origin of the copper-interaction concern with GHK-Cu. Whether ALA chelates the copper already coordinated within the GHK-Cu complex under physiologic conditions is not established in peer-reviewed literature as of this writing. The binding affinity of GHK for copper is so high that competitive displacement by ALA at typical supplemental concentrations may be minimal, but clinical data confirming this are absent.

The Pharmacodynamic Interactions You Need to Know

Two interactions carry enough published evidence to affect clinical decisions. They are not theoretical.

ALA Lowers Blood Glucose: The Evidence

ALA acts as an insulin sensitizer through activation of AMP-activated protein kinase (AMPK) and increased GLUT4 translocation to cell membranes [3]. A randomized controlled trial published in Diabetes Care found that intravenous ALA 600 mg/day for 3 weeks improved insulin-stimulated glucose disposal by 27% in patients with type 2 diabetes (P<0.001) [3]. Oral ALA at 600 mg/day reduced fasting plasma glucose by approximately 25 mg/dL compared with placebo in a separate 4-week trial [4].

GHK-Cu has not demonstrated direct hypoglycemic activity in published human trials. The concern here is additive: a patient already managing glucose with medication who adds ALA 600 mg/day may experience unexpectedly lower blood sugar readings. This qualifies as a pharmacodynamic drug-supplement interaction.

ALA and Thyroid Hormone: What the Data Show

A preclinical study in rodents showed that high-dose ALA supplementation reduced serum T4 by approximately 30% and altered thyroid peroxidase activity [5]. The proposed mechanism involves ALA's reduction of the oxidative environment required for thyroid hormone synthesis, given that thyroid peroxidase depends on hydrogen peroxide as a substrate.

Human data are sparse. A 2012 case report in Thyroid described a patient on stable levothyroxine whose TSH rose from 1.8 to 6.4 mIU/L after starting ALA 600 mg/day; TSH normalized within 8 weeks of stopping ALA [6]. This is a single case and cannot establish causation. Still, any patient on levothyroxine, liothyronine, or NP Thyroid who starts ALA should recheck TSH at 6 to 8 weeks.

GHK-Cu itself has no known direct effect on thyroid function in the published literature. The thyroid interaction is an ALA-only concern, not a GHK-Cu concern.

Is There a Copper Chelation Problem?

ALA chelates free copper(II) in aqueous solution [2]. The question is whether this matters when the copper is already tightly bound to the GHK tripeptide. Given GHK's extremely high copper-binding affinity (Kd approximately 10^-16 M), it is unlikely that ALA at physiologic concentrations would strip copper from the intact complex [1]. Topical GHK-Cu, which is the most common compounded form, also delivers copper primarily to skin tissue rather than to systemic circulation, further limiting the opportunity for ALA to chelate it after systemic absorption.

Injectable GHK-Cu does reach systemic circulation. For injectable formulations, a 2-hour separation between ALA ingestion and GHK-Cu injection is a reasonable precaution until human pharmacokinetic interaction data exist.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

Neither compound appears to be a significant CYP450 substrate, inducer, or inhibitor at supplemental doses. ALA is metabolized primarily by beta-oxidation in the liver [2], and GHK-Cu is degraded by peptidases to its constituent amino acids with the copper either incorporated into ceruloplasmin or excreted [1]. No shared metabolic pathway has been identified in the published literature.

The interactions described above, glucose lowering and thyroid hormone reduction, are both pharmacodynamic. They result from the biological effects of ALA on insulin signaling and thyroid peroxidase activity, not from one compound altering the absorption, distribution, or elimination of the other.

This distinction matters practically. Pharmacokinetic interactions often require strict timing or outright avoidance. Pharmacodynamic interactions, by contrast, can frequently be managed with dose adjustment and monitoring rather than complete avoidance.

Who Is Most at Risk?

Not every person taking GHK-Cu and ALA together faces equal risk. The following profiles warrant closer attention.

Patients on Insulin or Sulfonylureas

Adding ALA 600 mg/day to an existing regimen that includes insulin glargine, insulin lispro, glipizide, or glyburide creates a real additive hypoglycemia risk. The American Diabetes Association 2024 Standards of Care recommend that any new supplement with documented insulin-sensitizing effects be discussed with a clinician before starting [7]. Fasting glucose and post-prandial readings should be checked more frequently during the first 2 to 4 weeks of combined use.

Patients on Levothyroxine or Other Thyroid Medications

As detailed above, the single case report and rodent data together are enough to justify TSH monitoring at 6 to 8 weeks after starting ALA. The American Thyroid Association does not yet have a formal position statement on ALA-thyroid interactions, but clinical prudence supports this precaution [6].

Patients with Wilson's Disease or Copper-Metabolism Disorders

GHK-Cu introduces exogenous copper. ALA chelates copper. These opposing effects in a patient with an underlying copper-metabolism disorder could shift copper balance unpredictably. Use of GHK-Cu in Wilson's disease or Menkes disease should be discussed with a specialist regardless of ALA co-administration [8].

Dosing, Timing, and Practical Recommendations

The practical guidance below is derived from the mechanisms and evidence described above, not from a head-to-head GHK-Cu plus ALA clinical trial, because no such trial has been published.

Typical Dose Ranges in Clinical Use

Compounded injectable GHK-Cu preparations range from 0.5 mg to 2 mg per injection, typically administered 2 to 5 times per week. Topical GHK-Cu serums used in dermatology typically contain 0.1% to 3% GHK-Cu by weight.

Supplemental ALA doses range from 100 mg once daily for general antioxidant use to 600 mg once daily or twice daily for neuropathy or insulin sensitization. R-ALA is considered more bioavailable and is sometimes dosed at 100 to 300 mg daily to approximate the effect of 600 mg of racemic ALA [2].

The glucose-lowering and thyroid effects documented in trials were observed at 600 mg/day of racemic ALA [3, 4, 5]. Lower doses carry lower but not zero risk.

Recommended Timing Separation

For oral ALA and injectable GHK-Cu: a minimum 2-hour gap between ALA ingestion and the GHK-Cu injection allows ALA plasma concentration to begin declining before systemic copper exposure from the injection peaks. ALA's oral bioavailability is approximately 30%, and peak plasma levels occur within 30 to 60 minutes of ingestion, with a plasma half-life of roughly 30 minutes [2]. Waiting 2 hours means ALA concentration has dropped below 10% of peak by the time GHK-Cu copper reaches circulation.

For topical GHK-Cu and oral ALA: no timing separation is clinically necessary based on current evidence, because systemic copper exposure from topical preparations is minimal.

Monitoring Parameters

The following monitoring schedule is appropriate for combined use:

• Fasting blood glucose at baseline, week 2, and week 4 if the patient takes any glucose-lowering medication.
• TSH at baseline and at week 6 to 8 if the patient takes any thyroid medication.
• Serum copper and ceruloplasmin at baseline if the patient has a known copper-metabolism condition or takes high-dose injectable GHK-Cu (above 2 mg per injection, multiple times weekly).

What If You Are Already Taking Both?

If you are already taking ALA and GHK-Cu together and have experienced no adverse effects, that is reassuring but not conclusive. The glucose and thyroid effects of ALA are dose-dependent and may not be apparent without lab testing. The practical steps are:

1. Check fasting glucose once, even if you feel fine, if you take any diabetes medication.
2. Check TSH once if you take any thyroid medication and have not had labs in the past 2 months.
3. Confirm your GHK-Cu source is a licensed 503A compounding pharmacy, because unregulated peptide products introduce copper-content uncertainty. The FDA has issued guidance on compounded drug products that should inform sourcing decisions [9].
4. Inform your prescribing clinician that you are combining these two agents, so the combination is documented in your chart.

No intervention is needed beyond monitoring if labs are normal.

Special Populations

Pregnancy and Breastfeeding

ALA crosses the placenta in animal models, and adequate safety data in human pregnancy are not available [2]. GHK-Cu's safety in pregnancy has not been studied in controlled trials. Both agents should be avoided during pregnancy and breastfeeding unless a physician explicitly determines benefit outweighs risk.

Older Adults

Plasma GHK levels decline with age, which is part of the rationale for supplementation. Older adults are also more likely to be on polypharmacy regimens involving levothyroxine, insulin, or oral hypoglycemics. The interaction risks are, therefore, more clinically meaningful in this population. Dose-start low (ALA 100 mg/day rather than 600 mg/day) and titrate with monitoring.

People with Autoimmune Thyroid Disease

Hashimoto's thyroiditis and Graves' disease both involve oxidative stress in thyroid tissue. ALA's antioxidant effects could theoretically benefit or complicate this picture. Given the documented T4 reduction in animal studies [5], adding ALA in autoimmune thyroid disease requires thyroid function monitoring regardless of GHK-Cu co-administration.

Summary of the Evidence Base

The interaction between ALA and GHK-Cu is real but manageable. The strongest evidence concerns ALA alone, specifically its glucose-lowering effect documented in multiple RCTs [3, 4] and its thyroid hormone effect documented in animal studies with one supporting human case report [5, 6]. The copper chelation concern is mechanistically plausible but clinically unconfirmed at typical supplemental doses, given GHK's high copper-binding affinity [1].

No randomized trial has studied GHK-Cu and ALA in combination. The absence of such data means clinical decisions must rely on mechanism-based reasoning and individual patient risk assessment.

Patients without diabetes medication or thyroid medication who use topical GHK-Cu and ALA at doses of 100 to 300 mg/day face low and likely acceptable risk. Patients in higher-risk categories, as described above, need baseline labs and follow-up before proceeding.